{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:16:56Z","timestamp":1792682216325,"version":"4.5.0"},"reference-count":109,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001794","name":"The University of Queensland","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001794","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Febrile neutropenia (FN) is a life-threatening complication of chemotherapy. Although practice guidelines suggest the use of existing prediction models when making decisions to prevent and treat FN, recent evidence suggests that these models are limited in their discriminative ability. This study aims to systematically review and critically evaluate the recent literature to assess the question: what evidence-based clinical prediction models can be used to predict FN or its outcomes?<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>PubMed, EMBASE, Web of Science, and SCOPUS were searched for primary journal articles that developed or validated models that predicted FN or outcomes in patients with FN. Risk of bias was critically evaluated using the Prediction model Risk of Bias Assessment Tool (PROBAST).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Five thousand nine hundred nineteen articles were identified, of which 90 met inclusion criteria. Twenty-five studies predicted FN, and 65 studies predicted outcomes in patients with FN, including 28 that predicted mortality, 35 that predicted microbiological outcomes, and 35 that predicted other complications. Eight studies used machine learning methods in their development, and few studies were externally validated. All 90 studies were graded as high risk of bias using PROBAST.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Prediction models for FN and its outcomes demonstrate promising discriminatory ability; however, several limitations have prevented these from translating clinically. These limitations include variable FN definitions, high ROB in current models, limited external validation, and heterogeneous cohorts. Future work is needed to further develop and validate robust, well-evidenced models that can translate into clinical practice. This may best be achieved through machine learning and electronic medical record integration.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00520-025-09562-y","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T15:32:35Z","timestamp":1749051155000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Clinical prediction models for febrile neutropenia and its outcomes: a systematic review"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8661-1923","authenticated-orcid":false,"given":"Joshua","family":"Sheehy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8687-8230","authenticated-orcid":false,"given":"Marianne","family":"Gallanagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2475-9989","authenticated-orcid":false,"given":"Clair","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8050-6209","authenticated-orcid":false,"given":"Steven","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"issue":"10","key":"9562_CR1","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1002\/cncr.21847","volume":"106","author":"NM Kuderer","year":"2006","unstructured":"Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106(10):2258\u20132266. https:\/\/doi.org\/10.1002\/cncr.21847","journal-title":"Cancer"},{"issue":"1","key":"9562_CR2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/CCM.0b013e31822b50c2","volume":"40","author":"M Legrand","year":"2012","unstructured":"Legrand M, Max A, Peigne V, Mariotte E, Canet E, Debrumetz A et al (2012) Survival in neutropenic patients with severe sepsis or septic shock. Crit Care Med 40(1):43\u201349. https:\/\/doi.org\/10.1097\/CCM.0b013e31822b50c2","journal-title":"Crit Care Med"},{"issue":"4","key":"9562_CR3","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1093\/cid\/cir073","volume":"52","author":"AG Freifeld","year":"2011","unstructured":"Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA et al (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis\u202f: An Off Publi Infec Dis Soc Am 52(4):e56\u201393. https:\/\/doi.org\/10.1093\/cid\/cir073","journal-title":"Clin Infect Dis : An Off Publi Infec Dis Soc Am"},{"issue":"3","key":"9562_CR4","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1080\/21505594.2016.1156821","volume":"7","author":"G Gustinetti","year":"2016","unstructured":"Gustinetti G, Mikulska M (2016) Bloodstream infections in neutropenic cancer patients: A practical update. Virulence 7(3):280\u2013297. https:\/\/doi.org\/10.1080\/21505594.2016.1156821","journal-title":"Virulence"},{"issue":"14","key":"9562_CR5","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1200\/JCO.2017.77.6211","volume":"36","author":"RA Taplitz","year":"2018","unstructured":"Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK et al (2018) Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America clinical practice guideline update. J Clin Oncol 36(14):1443\u20131453. https:\/\/doi.org\/10.1200\/JCO.2017.77.6211","journal-title":"J Clin Oncol"},{"issue":"8","key":"9562_CR6","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s00520-004-0614-5","volume":"12","author":"A Uys","year":"2004","unstructured":"Uys A, Rapoport BL, Anderson R (2004) Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score. Support Care Cancer\u202f: Off J Multinatl Assoc Support Care Cancer 12(8):555\u2013560. https:\/\/doi.org\/10.1007\/s00520-004-0614-5","journal-title":"Support Care Cancer : Off J Multinatl Assoc Support Care Cancer"},{"issue":"25","key":"9562_CR7","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.1200\/jco.2005.03.9909","volume":"24","author":"J Klastersky","year":"2006","unstructured":"Klastersky J, Paesmans M, Georgala A, Muanza F, Plehiers B, Dubreucq L et al (2006) Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol\u202f: Off J Am Soc Clin Oncol 24(25):4129\u20134134. https:\/\/doi.org\/10.1200\/jco.2005.03.9909","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"key":"9562_CR8","doi-asserted-by":"publisher","first-page":"102922","DOI":"10.1016\/j.critrevonc.2020.102922","volume":"149","author":"B Zheng","year":"2020","unstructured":"Zheng B, Toarta C, Cheng W, Taljaard M, Reaume N, Perry JJ (2020) Accuracy of the Multinational Association of Supportive Care in Cancer (MASCC) and Clinical Index of Stable Febrile Neutropenia (CISNE) scores for predicting serious complications in adult patients with febrile neutropenia: A systematic review and meta-analysis. Crit Rev Oncol Hematol 149. https:\/\/doi.org\/10.1016\/j.critrevonc.2020.102922","journal-title":"Crit Rev Oncol Hematol"},{"issue":"8","key":"9562_CR9","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1007\/s00520-013-1787-6","volume":"21","author":"S Ahn","year":"2013","unstructured":"Ahn S, Lee YS, Lim KS, Lee JL (2013) Adding procalcitonin to the MASCC risk-index score could improve risk stratification of patients with febrile neutropenia. Support Care Cancer\u202f: Off J Multinatl Assoc Support Care Cancer 21(8):2303\u20132308. https:\/\/doi.org\/10.1007\/s00520-013-1787-6","journal-title":"Support Care Cancer : Off J Multinatl Assoc Support Care Cancer"},{"issue":"3","key":"9562_CR10","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.ygyno.2013.06.018","volume":"130","author":"CC Gunderson","year":"2013","unstructured":"Gunderson CC, Farrell R, Dinh BC, Thomas ED, Vesely SK, Lauer JK et al (2013) Inpatient versus outpatient management of neutropenic fever in gynecologic oncology patients: is risk stratification useful? Gynecol Oncol 130(3):411\u2013415. https:\/\/doi.org\/10.1016\/j.ygyno.2013.06.018","journal-title":"Gynecol Oncol"},{"issue":"11","key":"9562_CR11","doi-asserted-by":"publisher","first-page":"e1056","DOI":"10.1016\/j.ijid.2013.04.004","volume":"17","author":"S Kaya","year":"2013","unstructured":"Kaya S, K\u00f6ksal I, Mente\u015fe A, S\u00f6nmez M, S\u00fcmer A, Y\u0131ld\u0131r\u0131m SS et al (2013) The significance of serum urokinase plasminogen activation receptor (suPAR) in the diagnosis and follow-up of febrile neutropenic patients with hematologic malignancies. Int J Infect Dis 17(11):e1056\u2013e1059. https:\/\/doi.org\/10.1016\/j.ijid.2013.04.004","journal-title":"Int J Infect Dis"},{"issue":"4","key":"9562_CR12","doi-asserted-by":"publisher","first-page":"R169","DOI":"10.1186\/cc12848","volume":"17","author":"MM Luz Fiusa","year":"2013","unstructured":"Luz Fiusa MM, Costa-Lima C, de Souza GR, Vigorito AC, Penteado Aranha FJ, Lorand-Metze I et al (2013) A high angiopoietin-2\/angiopoietin-1 ratio is associated with a high risk of septic shock in patients with febrile neutropenia. Crit Care 17(4):R169. https:\/\/doi.org\/10.1186\/cc12848","journal-title":"Crit Care"},{"issue":"4","key":"9562_CR13","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/hon.2040","volume":"31","author":"JJ Lynn","year":"2013","unstructured":"Lynn JJ, Chen KF, Weng YM, Chiu TF (2013) Risk factors associated with complications in patients with chemotherapy-induced febrile neutropenia in emergency department. Hematol Oncol 31(4):189\u2013196. https:\/\/doi.org\/10.1002\/hon.2040","journal-title":"Hematol Oncol"},{"issue":"2","key":"9562_CR14","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s10156-012-0474-8","volume":"19","author":"T Matsumoto","year":"2013","unstructured":"Matsumoto T, Fujita M, Hirota T, Takeda S, Hirano R, Uchino J et al (2013) Elevation of serum C-reactive protein predicts failure of the initial antimicrobial treatment for febrile neutropenia with lung cancer. J Infect Chemother 19(2):202\u2013207. https:\/\/doi.org\/10.1007\/s10156-012-0474-8","journal-title":"J Infect Chemother"},{"issue":"4","key":"9562_CR15","doi-asserted-by":"publisher","first-page":"216","DOI":"10.4103\/2278-330x.119913","volume":"2","author":"M Meidani","year":"2013","unstructured":"Meidani M, Khorvash F, Abolghasemi H, Jamali B (2013) Procalcitonin and quantitative C-reactive protein role in the early diagnosis of sepsis in patients with febrile neutropenia. South Asian J Cancer 2(4):216\u2013219. https:\/\/doi.org\/10.4103\/2278-330x.119913","journal-title":"South Asian J Cancer"},{"issue":"2","key":"9562_CR16","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1590\/1414-431x20122397","volume":"46","author":"AF Ribeiro","year":"2013","unstructured":"Ribeiro AF, Nobre V, Neuenschwander LC, Teixeira AL, Xavier SG, Paula FD et al (2013) Use of inflammatory molecules to predict the occurrence of fever in onco-hematological patients with neutropenia. Braz J Med Biol Res 46(2):200\u2013206. https:\/\/doi.org\/10.1590\/1414-431x20122397","journal-title":"Braz J Med Biol Res"},{"issue":"11","key":"9562_CR17","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.3109\/10428194.2013.780287","volume":"54","author":"M Schwenkglenks","year":"2013","unstructured":"Schwenkglenks M, Bendall KL, Pfeil AM, Szabo Z, Pettengell R (2013) External validation of a risk model of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma. Leuk Lymphoma 54(11):2426\u20132432. https:\/\/doi.org\/10.3109\/10428194.2013.780287","journal-title":"Leuk Lymphoma"},{"key":"9562_CR18","doi-asserted-by":"publisher","unstructured":"Carmona-Bayonas A, Fonseca PJ, Font C, Mart\u00ednez-Garc\u00eda J, Torrella F, Urrego E, et al. Bacteremia in adult cancer patients with apparently stable febrile neutropenia: data from a cohort of 692 consecutive episodes from a single institution. J Community Support Oncol. 2014;12(9):312\u201320. https:\/\/doi.org\/10.12788\/jcso.0071","DOI":"10.12788\/jcso.0071"},{"issue":"6","key":"9562_CR19","doi-asserted-by":"publisher","first-page":"e96413","DOI":"10.1371\/journal.pone.0096413","volume":"9","author":"K Chen","year":"2014","unstructured":"Chen K, Zhang X, Deng H, Zhu L, Su F, Jia W et al (2014) Clinical predictive models for chemotherapy-induced febrile neutropenia in breast cancer patients: a validation study. PLoS ONE 9(6). https:\/\/doi.org\/10.1371\/journal.pone.0096413","journal-title":"PLoS ONE"},{"key":"9562_CR20","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.12659\/msm.892269","volume":"20","author":"M G\u00fcnalp","year":"2014","unstructured":"G\u00fcnalp M, Koyuno\u011flu M, G\u00fcrler S, Koca A, Ye\u015filkaya I, \u00d6ner E et al (2014) Independent factors for prediction of poor outcomes in patients with febrile neutropenia. Med Sci Monit 20:1826\u201332. https:\/\/doi.org\/10.12659\/msm.892269","journal-title":"Med Sci Monit"},{"issue":"4","key":"9562_CR21","doi-asserted-by":"publisher","first-page":"487","DOI":"10.4103\/0019-509x.175338","volume":"51","author":"VM Patil","year":"2014","unstructured":"Patil VM, Chakarborty S, Kumar MS, Geetha M, Dev S, Samuel S et al (2014) An audit of febrile neutropenia cases from a rural cancer center in India. Indian J Cancer 51(4):487\u2013490. https:\/\/doi.org\/10.4103\/0019-509x.175338","journal-title":"Indian J Cancer"},{"issue":"1","key":"9562_CR22","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/1471-2407-14-201","volume":"14","author":"AM Pfeil","year":"2014","unstructured":"Pfeil AM, Vulsteke C, Paridaens R, Dieudonn\u00e9 A-S, Pettengell R, Hatse S et al (2014) Multivariable regression analysis of febrile neutropenia occurrence in early breast cancer patients receiving chemotherapy assessing patient-related, chemotherapy-related and genetic risk factors. BMC Cancer 14(1):201. https:\/\/doi.org\/10.1186\/1471-2407-14-201","journal-title":"BMC Cancer"},{"issue":"2","key":"9562_CR23","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1093\/cid\/ciu260","volume":"59","author":"SA Shelburne 3rd","year":"2014","unstructured":"Shelburne SA 3rd, Lasky RE, Sahasrabhojane P, Tarrand JT, Rolston KV (2014) Development and validation of a clinical model to predict the presence of \u03b2-lactam resistance in viridans group streptococci causing bacteremia in neutropenic cancer patients. Clin Infect Dis\u202f: An Off Publi Infec Dis Soc Am 59(2):223\u2013230. https:\/\/doi.org\/10.1093\/cid\/ciu260","journal-title":"Clin Infect Dis : An Off Publi Infec Dis Soc Am"},{"issue":"3","key":"9562_CR24","doi-asserted-by":"publisher","first-page":"37","DOI":"10.7812\/tpp\/14-188","volume":"19","author":"RA Bitar","year":"2015","unstructured":"Bitar RA (2015) Utility of the Multinational Association for Supportive Care in Cancer (MASCC) risk index score as a criterion for nonadmission in febrile neutropenic patients with solid tumors. Perm J 19(3):37\u201347. https:\/\/doi.org\/10.7812\/tpp\/14-188","journal-title":"Perm J"},{"issue":"6","key":"9562_CR25","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1007\/s00520-014-2531-6","volume":"23","author":"H Bozcuk","year":"2015","unstructured":"Bozcuk H, Y\u0131ld\u0131z M, Arta\u00e7 M, Kocer M, Kaya \u00c7, Ulukal E et al (2015) A prospectively validated nomogram for predicting the risk of chemotherapy-induced febrile neutropenia: a multicenter study. Support Care Cancer\u202f: Off J Multinatl Assoc Support Care Cancer 23(6):1759\u20131767. https:\/\/doi.org\/10.1007\/s00520-014-2531-6","journal-title":"Support Care Cancer : Off J Multinatl Assoc Support Care Cancer"},{"issue":"5","key":"9562_CR26","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1200\/jco.2014.57.2347","volume":"33","author":"A Carmona-Bayonas","year":"2015","unstructured":"Carmona-Bayonas A, Jim\u00e9nez-Fonseca P, Virizuela Echaburu J, Antonio M, Font C, Biosca M et al (2015) Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study. J Clin Oncol\u202f: Off J Am Soc Clin Oncol 33(5):465\u2013471. https:\/\/doi.org\/10.1200\/jco.2014.57.2347","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"key":"9562_CR27","doi-asserted-by":"publisher","unstructured":"Garc\u00eda de Guadiana-Romualdo L, Espa\u00f1ol-Morales I, Cerezuela-Fuentes P, Consuegra-S\u00e1nchez L, Hernando-Holgado A, Esteban-Torrella P, et al (2015) Value of lipopolysaccharide binding protein as diagnostic marker of infection in adult cancer patients with febrile neutropenia: comparison with C-reactive protein, procalcitonin, and interleukin 6. Support Care Cancer : Off J Multinatl Assoc Support Care Cancer 23(7):2175\u201382. https:\/\/doi.org\/10.1007\/s00520-014-2589-1","DOI":"10.1007\/s00520-014-2589-1"},{"issue":"1","key":"9562_CR28","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3109\/10428194.2014.911864","volume":"56","author":"X Liu","year":"2015","unstructured":"Liu X, Wang DF, Fang Y, Ye WF, Liu S, Lou N (2015) Initial procalcitonin level predicts infection and its outcome in patients with non-Hodgkin lymphoma with febrile neutropenia. Leuk Lymphoma 56(1):85\u201391. https:\/\/doi.org\/10.3109\/10428194.2014.911864","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"9562_CR29","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1007\/s00520-014-2582-8","volume":"23","author":"BL Marini","year":"2015","unstructured":"Marini BL, Hough SM, Gregg KS, Abu-Seir H, Nagel JL (2015) Risk factors for piperacillin\/tazobactam-resistant Gram-negative infection in hematology\/oncology patients with febrile neutropenia. Support Care Cancer 23(8):2287\u20132295. https:\/\/doi.org\/10.1007\/s00520-014-2582-8","journal-title":"Support Care Cancer"},{"issue":"4","key":"9562_CR30","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3109\/00365548.2014.985711","volume":"47","author":"AK Purhonen","year":"2015","unstructured":"Purhonen AK, Juutilainen A, V\u00e4nsk\u00e4 M, Lehtikangas M, Lakkisto P, H\u00e4m\u00e4l\u00e4inen S et al (2015) Human plasma cell-free DNA as a predictor of infectious complications of neutropenic fever in hematological patients. Infect Dis (London, England) 47(4):255\u2013259. https:\/\/doi.org\/10.3109\/00365548.2014.985711","journal-title":"Infect Dis (London, England)"},{"issue":"1","key":"9562_CR31","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s10147-015-0853-0","volume":"21","author":"S Ahn","year":"2016","unstructured":"Ahn S, Lee YS, Lee JL, Lim KS, Yoon SC (2016) A new prognostic model for chemotherapy-induced febrile neutropenia. Int J Clin Oncol 21(1):46\u201352. https:\/\/doi.org\/10.1007\/s10147-015-0853-0","journal-title":"Int J Clin Oncol"},{"issue":"11","key":"9562_CR32","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1038\/bjc.2016.118","volume":"114","author":"PJ Fonseca","year":"2016","unstructured":"Fonseca PJ, Carmona-Bayonas A, Garc\u00eda IM, Marcos R, Casta\u00f1\u00f3n E, Antonio M et al (2016) A nomogram for predicting complications in patients with solid tumours and seemingly stable febrile neutropenia. Br J Cancer 114(11):1191\u20131198. https:\/\/doi.org\/10.1038\/bjc.2016.118","journal-title":"Br J Cancer"},{"issue":"6","key":"9562_CR33","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.annemergmed.2016.11.007","volume":"69","author":"CJ Coyne","year":"2017","unstructured":"Coyne CJ, Le V, Brennan JJ, Castillo EM, Shatsky RA, Ferran K et al (2017) Application of the MASCC and CISNE risk-stratification scores to identify low-risk febrile neutropenic patients in the emergency department. Ann Emerg Med 69(6):755\u2013764. https:\/\/doi.org\/10.1016\/j.annemergmed.2016.11.007","journal-title":"Ann Emerg Med"},{"issue":"2","key":"9562_CR34","doi-asserted-by":"publisher","first-page":"167","DOI":"10.4274\/tjh.2016.0123","volume":"34","author":"N Efe \u0130ris","year":"2017","unstructured":"Efe \u0130ris N, Y\u0131ld\u0131rmak T, Gedik H, \u015eim\u015fek F, Ayd\u0131n D, Demirel N et al (2017) Could neutrophil CD64 expression be used as a diagnostic parameter of bacteremia in patients with febrile neutropenia? Turk J Haematol 34(2):167\u2013173. https:\/\/doi.org\/10.4274\/tjh.2016.0123","journal-title":"Turk J Haematol"},{"issue":"5","key":"9562_CR35","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1007\/s00520-016-3567-6","volume":"25","author":"M Kim","year":"2017","unstructured":"Kim M, Ahn S, Kim WY, Sohn CH, Seo DW, Lee YS et al (2017) Predictive performance of the quick Sequential Organ Failure Assessment score as a screening tool for sepsis, mortality, and intensive care unit admission in patients with febrile neutropenia. Support Care Cancer\u202f: Off J Multinatl Assoc Support Care Cancer 25(5):1557\u20131562. https:\/\/doi.org\/10.1007\/s00520-016-3567-6","journal-title":"Support Care Cancer : Off J Multinatl Assoc Support Care Cancer"},{"key":"9562_CR36","doi-asserted-by":"publisher","first-page":"9805609","DOI":"10.1155\/2017\/9805609","volume":"2017","author":"S Korpelainen","year":"2017","unstructured":"Korpelainen S, Intke C, H\u00e4m\u00e4l\u00e4inen S, Jantunen E, Juutilainen A, Pulkki K (2017) Soluble CD14 as a diagnostic and prognostic biomarker in hematological patients with febrile neutropenia. Dis Markers 2017:9805609. https:\/\/doi.org\/10.1155\/2017\/9805609","journal-title":"Dis Markers"},{"issue":"12","key":"9562_CR37","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1007\/s00277-017-3128-1","volume":"96","author":"CS Michel","year":"2017","unstructured":"Michel CS, Teschner D, Wagner EM, Theobald M, Radsak MP (2017) Diagnostic value of sTREM-1, IL-8, PCT, and CRP in febrile neutropenia after autologous stem cell transplantation. Ann Hematol 96(12):2095\u20132101. https:\/\/doi.org\/10.1007\/s00277-017-3128-1","journal-title":"Ann Hematol"},{"issue":"3","key":"9562_CR38","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s12288-016-0730-7","volume":"33","author":"M Taj","year":"2017","unstructured":"Taj M, Nadeem M, Maqsood S, Shah T, Farzana T, Shamsi TS (2017) Validation of MASCC score for risk stratification in patients of hematological disorders with febrile neutropenia. Indian J Hematol Blood Transfus 33(3):355\u2013360. https:\/\/doi.org\/10.1007\/s12288-016-0730-7","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"9","key":"9562_CR39","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1007\/s00520-017-3696-6","volume":"25","author":"XJ Wang","year":"2017","unstructured":"Wang XJ, Goh DYT, Dorajoo SR, Chan A (2017) The prognostic performance of adding patient-reported outcomes to the MASCC risk index to identify low-risk febrile neutropenia patients with solid tumors and lymphomas. Support Care Cancer\u202f: Off J Multinatl Assoc Support Care Cancer 25(9):2815\u20132822. https:\/\/doi.org\/10.1007\/s00520-017-3696-6","journal-title":"Support Care Cancer : Off J Multinatl Assoc Support Care Cancer"},{"key":"9562_CR40","doi-asserted-by":"publisher","unstructured":"Aagaard T, Roen A, Reekie J, Daugaard G, Brown PN, Specht L, et al. Development and validation of a risk score for febrile neutropenia after chemotherapy in patients with cancer: the FENCE score. JNCI cancer spectrum. 2018;2(4):pky053. https:\/\/doi.org\/10.1093\/jncics\/pky053","DOI":"10.1093\/jncics\/pky053"},{"issue":"5","key":"9562_CR41","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1007\/s00520-017-3985-0","volume":"26","author":"S Ahn","year":"2018","unstructured":"Ahn S, Rice TW, Yeung SJ, Cooksley T (2018) Comparison of the MASCC and CISNE scores for identifying low-risk neutropenic fever patients: analysis of data from three emergency departments of cancer centers in three continents. Support Care Cancer\u202f: Off J Multinatl Assoc Support Care Cancer 26(5):1465\u20131470. https:\/\/doi.org\/10.1007\/s00520-017-3985-0","journal-title":"Support Care Cancer : Off J Multinatl Assoc Support Care Cancer"},{"key":"9562_CR42","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13161","author":"C Intke","year":"2018","unstructured":"Intke C, Korpelainen S, H\u00e4m\u00e4l\u00e4inen S, V\u00e4nsk\u00e4 M, Koivula I, Jantunen E et al (2018) Interleukin-1 receptor antagonist as a biomarker of sepsis in neutropenic haematological patients. Eur J Haematol. https:\/\/doi.org\/10.1111\/ejh.13161","journal-title":"Eur J Haematol"},{"issue":"9","key":"9562_CR43","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1159\/000488688","volume":"41","author":"D Kauffmann-Guerrero","year":"2018","unstructured":"Kauffmann-Guerrero D, Kahnert K, Syunyaeva Z, Tufman A, Huber RM (2018) Pretherapeutic inflammation predicts febrile neutropenia and reduced progression-free survival after first-line chemotherapy in SCLC. Oncol Res Treat 41(9):506\u2013512. https:\/\/doi.org\/10.1159\/000488688","journal-title":"Oncol Res Treat"},{"issue":"5","key":"9562_CR44","doi-asserted-by":"publisher","first-page":"e0197049","DOI":"10.1371\/journal.pone.0197049","volume":"13","author":"RS Kelly","year":"2018","unstructured":"Kelly RS, Lasky-Su J, Yeung SJ, Stone RM, Caterino JM, Hagan SC et al (2018) Integrative omics to detect bacteremia in patients with febrile neutropenia. PLoS ONE 13(5). https:\/\/doi.org\/10.1371\/journal.pone.0197049","journal-title":"PLoS ONE"},{"issue":"8","key":"9562_CR45","doi-asserted-by":"publisher","first-page":"4121","DOI":"10.1002\/cam4.1580","volume":"7","author":"Y Li","year":"2018","unstructured":"Li Y, Family L, Chen LH, Page JH, Klippel Z, Xu L et al (2018) Value of incorporating newly identified risk factors into risk prediction for chemotherapy-induced febrile neutropenia. Cancer Med 7(8):4121\u20134131. https:\/\/doi.org\/10.1002\/cam4.1580","journal-title":"Cancer Med"},{"issue":"12","key":"9562_CR46","doi-asserted-by":"publisher","first-page":"e0210019","DOI":"10.1371\/journal.pone.0210019","volume":"13","author":"H Moon","year":"2018","unstructured":"Moon H, Choi YJ, Sim SH (2018) Validation of the Clinical Index of Stable Febrile Neutropenia (CISNE) model in febrile neutropenia patients visiting the emergency department. Can it guide emergency physicians to a reasonable decision on outpatient vs. inpatient treatment? PLoS One 13(12):e0210019. https:\/\/doi.org\/10.1371\/journal.pone.0210019","journal-title":"PLoS One"},{"issue":"3","key":"9562_CR47","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/bcp.13477","volume":"84","author":"I Netterberg","year":"2018","unstructured":"Netterberg I, Karlsson MO, Nielsen EI, Quartino AL, Lindman H, Friberg LE (2018) The risk of febrile neutropenia in breast cancer patients following adjuvant chemotherapy is predicted by the time course of interleukin-6 and C-reactive protein by modelling. Br J Clin Pharmacol 84(3):490\u2013500. https:\/\/doi.org\/10.1111\/bcp.13477","journal-title":"Br J Clin Pharmacol"},{"issue":"27","key":"9562_CR48","doi-asserted-by":"publisher","first-page":"18970","DOI":"10.18632\/oncotarget.24863","volume":"9","author":"M Shimanuki","year":"2018","unstructured":"Shimanuki M, Imanishi Y, Sato Y, Nakahara N, Totsuka D, Sato E et al (2018) Pretreatment monocyte counts and neutrophil counts predict the risk for febrile neutropenia in patients undergoing TPF chemotherapy for head and neck squamous cell carcinoma. Oncotarget 9(27):18970\u201384. https:\/\/doi.org\/10.18632\/oncotarget.24863","journal-title":"Oncotarget"},{"key":"9562_CR49","doi-asserted-by":"publisher","unstructured":"Garc\u00eda de Guadiana-Romualdo L, Cerezuela-Fuentes P, Espa\u00f1ol-Morales I, Esteban-Torrella P, Jim\u00e9nez-Santos E, Hernando-Holgado A, et al (2019) Prognostic value of procalcitonin and lipopolysaccharide binding protein in cancer patients with chemotherapy-associated febrile neutropenia presenting to an emergency department. Biochem Med (Zagreb) 29(1):010702. https:\/\/doi.org\/10.11613\/bm.2019.010702","DOI":"10.11613\/bm.2019.010702"},{"issue":"2","key":"9562_CR50","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1097\/shk.0000000000001256","volume":"52","author":"YJ Kim","year":"2019","unstructured":"Kim YJ, Kang J, Ryoo SM, Ahn S, Huh JW, Kim WY (2019) Platelet-lymphocyte ratio after granulocyte colony stimulating factor administration: an early prognostic marker in septic shock patients with chemotherapy-induced febrile neutropenia. Shock 52(2):160\u2013165. https:\/\/doi.org\/10.1097\/shk.0000000000001256","journal-title":"Shock"},{"issue":"1","key":"9562_CR51","doi-asserted-by":"publisher","first-page":"e2019047","DOI":"10.4084\/mjhid.2019.047","volume":"11","author":"I Kostic","year":"2019","unstructured":"Kostic I, Gurrieri C, Piva E, Semenzato G, Plebani M, Caputo I et al (2019) Comparison of presepsin, procalcitonin, interleukin-8 and C-reactive protein in predicting bacteraemia in febrile neutropenic adult patients with haematological malignancies. Mediterr J Hematol Infect Dis 11(1). https:\/\/doi.org\/10.4084\/mjhid.2019.047","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"10","key":"9562_CR52","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1080\/10428194.2019.1581928","volume":"60","author":"X Luo","year":"2019","unstructured":"Luo X, Chen S, Zhang J, Ren J, Chen M, Lin K et al (2019) Procalcitonin as a marker of Gram-negative bloodstream infections in hematological patients with febrile neutropenia. Leuk Lymphoma 60(10):2441\u20132448. https:\/\/doi.org\/10.1080\/10428194.2019.1581928","journal-title":"Leuk Lymphoma"},{"key":"9562_CR53","doi-asserted-by":"publisher","first-page":"4175960","DOI":"10.1155\/2019\/4175960","volume":"2019","author":"C Perazzoli","year":"2019","unstructured":"Perazzoli C, Parra RS, Feitosa MR, Sfoggia E, Sim\u00f5es BP, Rocha JJR et al (2019) A novel severity score index for febrile neutropenic patients with colorectal diseases. Gastroenterol Res Pract 2019:4175960. https:\/\/doi.org\/10.1155\/2019\/4175960","journal-title":"Gastroenterol Res Pract"},{"key":"9562_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/jgo.19.00147","volume":"5","author":"R Shilpakar","year":"2019","unstructured":"Shilpakar R, Paudel BD, Neupane P, Shah A, Acharya B, Dulal S et al (2019) Procalcitonin and C-Reactive protein as markers of bacteremia in patients with febrile neutropenia who receive chemotherapy for acute leukemia: a prospective study from Nepal. J Glob Oncol 5:1\u20136. https:\/\/doi.org\/10.1200\/jgo.19.00147","journal-title":"J Glob Oncol"},{"issue":"1","key":"9562_CR55","doi-asserted-by":"publisher","first-page":"e2019023","DOI":"10.4084\/mjhid.2019.023","volume":"11","author":"A Verlinden","year":"2019","unstructured":"Verlinden A, De Vroey V, Goossens H, Roelant E, Van De Velde AL, Berneman ZN et al (2019) Comparison of the power of procalcitonin and c-reactive protein to discriminate between different aetiologies of fever in prolonged profound neutropenia: a single-centre prospective observational study. Mediterr J Hematol Infect Dis 11(1). https:\/\/doi.org\/10.4084\/mjhid.2019.023","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"12","key":"9562_CR56","doi-asserted-by":"publisher","first-page":"e0225765","DOI":"10.1371\/journal.pone.0225765","volume":"14","author":"M Yang","year":"2019","unstructured":"Yang M, Choi SJ, Lee J, Lee DG, Kim YJ, Park YJ et al (2019) Serum procalcitonin as an independent diagnostic markers of bacteremia in febrile patients with hematologic malignancies. PLoS ONE 14(12). https:\/\/doi.org\/10.1371\/journal.pone.0225765","journal-title":"PLoS ONE"},{"issue":"2","key":"9562_CR57","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/ijc.32249","volume":"146","author":"T Aagaard","year":"2020","unstructured":"Aagaard T, Reekie J, Roen A, Daugaard G, Specht L, Sengel\u00f8v H et al (2020) Development and validation of a cycle-specific risk score for febrile neutropenia during chemotherapy cycles 2\u20136 in patients with solid cancers: The (CSR) FENCE score. Int J Cancer 146(2):321\u2013328. https:\/\/doi.org\/10.1002\/ijc.32249","journal-title":"Int J Cancer"},{"key":"9562_CR58","doi-asserted-by":"publisher","unstructured":"Chantharakhit C, Sujaritvanichpong, N (2020) Pretreatment absolute neutrophil-to-lymphocyte ratio (NLR) predict the risk for febrile neutropenia in the first cycle adjuvant chemotherapy for breast cancer. Asian Pacific J Cancer Biol 5(3). https:\/\/doi.org\/10.31557\/apjcb.2020.5.3.81-87","DOI":"10.31557\/apjcb.2020.5.3.81-87"},{"issue":"1","key":"9562_CR59","doi-asserted-by":"publisher","first-page":"14803","DOI":"10.1038\/s41598-020-71927-6","volume":"10","author":"BJ Cho","year":"2020","unstructured":"Cho BJ, Kim KM, Bilegsaikhan SE, Suh YJ (2020) Machine learning improves the prediction of febrile neutropenia in Korean inpatients undergoing chemotherapy for breast cancer. Sci Rep 10(1):14803. https:\/\/doi.org\/10.1038\/s41598-020-71927-6","journal-title":"Sci Rep"},{"key":"9562_CR60","doi-asserted-by":"publisher","first-page":"104140","DOI":"10.1016\/j.ijmedinf.2020.104140","volume":"139","author":"X Du","year":"2020","unstructured":"Du X, Min J, Shah CP, Bishnoi R, Hogan WR, Lemas DJ (2020) Predicting in-hospital mortality of patients with febrile neutropenia using machine learning models. Int J Med Informatics 139. https:\/\/doi.org\/10.1016\/j.ijmedinf.2020.104140","journal-title":"Int J Med Informatics"},{"issue":"12","key":"9562_CR61","doi-asserted-by":"publisher","first-page":"e0289","DOI":"10.1097\/cce.0000000000000289","volume":"2","author":"EA Gulleen","year":"2020","unstructured":"Gulleen EA, Ameko MK, Ainsworth JE, Barnes LE, Moore CC (2020) Predictive models of fever, ICU transfer, and mortality in hospitalized patients with neutropenia. Crit Care Explor 2(12). https:\/\/doi.org\/10.1097\/cce.0000000000000289","journal-title":"Crit Care Explor"},{"key":"9562_CR62","doi-asserted-by":"publisher","first-page":"102445","DOI":"10.1016\/j.bcmd.2020.102445","volume":"84","author":"R Halder","year":"2020","unstructured":"Halder R, Seth T, Chaturvedi PK, Mishra P, Mahapatra M, Pati HP et al (2020) Comparison of CRP and procalcitonin for etiological diagnosis of fever during febrile neutropenia in hematology patients- an experience from a tertiary care center in Northern India. Blood Cells Mol Dis 84. https:\/\/doi.org\/10.1016\/j.bcmd.2020.102445","journal-title":"Blood Cells Mol Dis"},{"issue":"6","key":"9562_CR63","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1111\/ejh.13500","volume":"105","author":"M Lappalainen","year":"2020","unstructured":"Lappalainen M, H\u00e4m\u00e4l\u00e4inen S, Romppanen T, Pulkki K, Py\u00f6r\u00e4l\u00e4 M, Koivula I et al (2020) Febrile neutropenia in patients with acute myeloid leukemia: outcome in relation to qSOFA score, C-reactive protein, and blood culture findings. Eur J Haematol 105(6):731\u2013740. https:\/\/doi.org\/10.1111\/ejh.13500","journal-title":"Eur J Haematol"},{"key":"9562_CR64","doi-asserted-by":"publisher","unstructured":"Mar\u00edn K, Basantes E, Caballero H, Gangotena A, Figueroa V, Del Pozo G (2020) Procalcitonin as early predictor of bacteremia in critically ill neutropenic patients. Gaceta Mexicana de Oncolog\u00eda 19. https:\/\/doi.org\/10.24875\/j.gamo.M19000194","DOI":"10.24875\/j.gamo.M19000194"},{"issue":"11","key":"9562_CR65","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1016\/j.ajem.2019.09.016","volume":"38","author":"R Mohindra","year":"2020","unstructured":"Mohindra R, Mathew R, Yadav S, Aggarwal P (2020) CISNE versus MASCC: identifying low risk febrile neutropenic patients. Am J Emerg Med 38(11):2259\u20132263. https:\/\/doi.org\/10.1016\/j.ajem.2019.09.016","journal-title":"Am J Emerg Med"},{"key":"9562_CR66","doi-asserted-by":"publisher","unstructured":"\u00d6demi\u015f \u0130, K\u00f6se \u015e, Senger SS, Akbulut \u0130, \u00c7elik D (2020) The diagnostic value of monocyte chemoattractant protein-1, compared with procalcitonin, C-reactive protein, and lactate in bacteremia estimation for patients with febrile neutropenia. Revista Romana de Medicina de Laborator 28(4):419\u201326. https:\/\/doi.org\/10.2478\/rrlm-2020-0036","DOI":"10.2478\/rrlm-2020-0036"},{"issue":"2","key":"9562_CR67","doi-asserted-by":"publisher","first-page":"e0229828","DOI":"10.1371\/journal.pone.0229828","volume":"15","author":"O Peyrony","year":"2020","unstructured":"Peyrony O, Gerlier C, Barla I, Ellouze S, Legay L, Azoulay E et al (2020) Antibiotic prescribing and outcomes in cancer patients with febrile neutropenia in the emergency department. PLoS ONE 15(2). https:\/\/doi.org\/10.1371\/journal.pone.0229828","journal-title":"PLoS ONE"},{"issue":"11","key":"9562_CR68","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.1080\/10428194.2020.1779253","volume":"61","author":"S Shimony","year":"2020","unstructured":"Shimony S, Rozovski U, Sudry N, Yeshurun M, Yahav D, Raanani P et al (2020) Early detection of infectious complications during induction therapy for acute leukemia with serial C-reactive protein biomarker assessment. Leuk Lymphoma 61(11):2708\u20132713. https:\/\/doi.org\/10.1080\/10428194.2020.1779253","journal-title":"Leuk Lymphoma"},{"key":"9562_CR69","doi-asserted-by":"publisher","first-page":"963","DOI":"10.2147\/tcrm.S318370","volume":"17","author":"O Alshari","year":"2021","unstructured":"Alshari O, Al Zu\u2019bi YO, Al Sharie AH, Wafai FH, Aleshawi AJ, Atawneh FH et al (2021) Evaluating the prognostic role of monocytopenia in chemotherapy-induced febrile neutropenia patients treated with granulocyte colony-stimulating factor. Ther Clin Risk Manag 17:963\u2013973. https:\/\/doi.org\/10.2147\/tcrm.S318370","journal-title":"Ther Clin Risk Manag"},{"issue":"10","key":"9562_CR70","doi-asserted-by":"publisher","first-page":"5905","DOI":"10.1007\/s00520-021-06154-4","volume":"29","author":"PV Bhardwaj","year":"2021","unstructured":"Bhardwaj PV, Emmich M, Knee A, Ali F, Walia R, Roychowdhury P et al (2021) Use of MASCC score in the inpatient management of febrile neutropenia: a single-center retrospective study. Support Care Cancer\u202f: Off J Multinatl Assoc Support Care Cancer 29(10):5905\u20135914. https:\/\/doi.org\/10.1007\/s00520-021-06154-4","journal-title":"Support Care Cancer : Off J Multinatl Assoc Support Care Cancer"},{"issue":"7","key":"9562_CR71","doi-asserted-by":"publisher","first-page":"4089","DOI":"10.1007\/s00520-020-05924-w","volume":"29","author":"T Cetintepe","year":"2021","unstructured":"Cetintepe T, Cetintepe L, Solmaz S, Cal\u0131k S, Ugur MC, Gediz F et al (2021) Determination of the relationship between mortality and SOFA, qSOFA, MASCC scores in febrile neutropenic patients monitored in the intensive care unit. Support Care Cancer\u202f: Off J Multinatl Assoc Support Care Cancer 29(7):4089\u20134094. https:\/\/doi.org\/10.1007\/s00520-020-05924-w","journal-title":"Support Care Cancer : Off J Multinatl Assoc Support Care Cancer"},{"issue":"23","key":"9562_CR72","doi-asserted-by":"publisher","first-page":"8475","DOI":"10.1002\/cam4.4355","volume":"10","author":"P Chaftari","year":"2021","unstructured":"Chaftari P, Chaftari AM, Hachem R, Yeung SJ, Dagher H, Jiang Y et al (2021) The role of procalcitonin in identifying high-risk cancer patients with febrile neutropenia: a useful alternative to the multinational association for supportive care in cancer score. Cancer Med 10(23):8475\u20138482. https:\/\/doi.org\/10.1002\/cam4.4355","journal-title":"Cancer Med"},{"issue":"2","key":"9562_CR73","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s40121-021-00438-2","volume":"10","author":"C Garcia-Vidal","year":"2021","unstructured":"Garcia-Vidal C, Puerta-Alcalde P, Cardozo C, Orellana MA, Besanson G, Lagunas J et al (2021) Machine learning to assess the risk of multidrug-resistant gram-negative bacilli infections in febrile neutropenic hematological patients. Infect Dis and Ther 10(2):971\u2013983. https:\/\/doi.org\/10.1007\/s40121-021-00438-2","journal-title":"Infect Dis and Ther"},{"key":"9562_CR74","doi-asserted-by":"publisher","unstructured":"Monuszko KA, Albright B, Katherine Montes De Oca M, Thao Thi Nguyen N, Havrilesky LJ, Davidson BA (2021) Evaluation of the Clinical Index of Stable Febrile Neutropenia risk stratification system for management of febrile neutropenia in gynecologic oncology patients. Gynecol Oncol Rep 37:100853. https:\/\/doi.org\/10.1016\/j.gore.2021.100853","DOI":"10.1016\/j.gore.2021.100853"},{"issue":"7","key":"9562_CR75","doi-asserted-by":"publisher","first-page":"e0253842","DOI":"10.1371\/journal.pone.0253842","volume":"16","author":"R Moustafa","year":"2021","unstructured":"Moustafa R, Albouni T, Aziz G (2021) The role of procalcitonin and presepsin in the septic febrile neutropenia in acute leukemia patients. PLoS ONE 16(7). https:\/\/doi.org\/10.1371\/journal.pone.0253842","journal-title":"PLoS ONE"},{"key":"9562_CR76","doi-asserted-by":"publisher","first-page":"102586","DOI":"10.1016\/j.bcmd.2021.102586","volume":"90","author":"AL Reyes Mondrag\u00f3n","year":"2021","unstructured":"Reyes Mondrag\u00f3n AL, Cant\u00fa-Rodr\u00edguez OG, Garza-Acosta AC, Guti\u00e9rrez-Aguirre CH, Colunga Pedraza PR, Del Carmen T-A et al (2021) Performance of serum procalcitonin as a biochemical predictor of death in hematology patients with febrile neutropenia. Blood Cells Mol Dis 90. https:\/\/doi.org\/10.1016\/j.bcmd.2021.102586","journal-title":"Blood Cells Mol Dis"},{"key":"9562_CR77","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ijregi.2021.09.002","volume":"1","author":"C Sereeaphinan","year":"2021","unstructured":"Sereeaphinan C, Kanchanasuwan S, Julamanee J (2021) Mortality-associated clinical risk factors in patients with febrile neutropenia: A retrospective study. IJID Reg 1:5\u201311. https:\/\/doi.org\/10.1016\/j.ijregi.2021.09.002","journal-title":"IJID Reg"},{"issue":"5","key":"9562_CR78","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.jemermed.2020.12.010","volume":"60","author":"S Yadav","year":"2021","unstructured":"Yadav S, Mathew R, Sahu AK, Jamshed N, Mohindra R, Aggarwal P et al (2021) Prognostic value of serum procalcitonin levels in patients with febrile neutropenia presenting to the emergency department. J Emerg Med 60(5):641\u2013647. https:\/\/doi.org\/10.1016\/j.jemermed.2020.12.010","journal-title":"J Emerg Med"},{"issue":"3","key":"9562_CR79","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1007\/s00520-021-06681-0","volume":"30","author":"H Bozcuk","year":"2022","unstructured":"Bozcuk H, Co\u015fkun H, \u0130lhan Y, G\u00f6ksu SS, Y\u0131ld\u0131z M, Bayram S et al (2022) Prospective external validation of an updated algorithm to quantify risk of febrile neutropenia in cancer patients after a cycle of chemotherapy. Support Care Cancer\u202f: Off J Multinatl Assoc Support Care Cancer 30(3):2621\u20132629. https:\/\/doi.org\/10.1007\/s00520-021-06681-0","journal-title":"Support Care Cancer : Off J Multinatl Assoc Support Care Cancer"},{"key":"9562_CR80","doi-asserted-by":"publisher","unstructured":"Buchan CA, Li HO, Herry CL, Scales N, MacPherson P, Faller E, et al (2022) Early warning of infection in patients undergoing hematopoietic stem cell transplantation using heart rate variability and serum biomarkers. Transplant Cell Ther 28(3):166.e1-.e8. https:\/\/doi.org\/10.1016\/j.jtct.2021.04.023","DOI":"10.1016\/j.jtct.2021.04.023"},{"key":"9562_CR81","doi-asserted-by":"publisher","unstructured":"Carc\u00f2 D, Markovic U, Castorina P, Iachelli V, Pace T, Guardo P, et al (2022) C-reactive protein monitoring and clinical presentation of fever as predictive factors of prolonged febrile neutropenia and blood culture positivity after autologous hematopoietic stem cell transplantation-single-center real-life experience. J Clin Med 11(2). https:\/\/doi.org\/10.3390\/jcm11020312","DOI":"10.3390\/jcm11020312"},{"issue":"1","key":"9562_CR82","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1080\/07853890.2022.2031271","volume":"54","author":"A Choi","year":"2022","unstructured":"Choi A, Park I, Lee HS, Chung J, Kim MJ, Park YS (2022) Usefulness of complete blood count parameters to predict poor outcomes in cancer patients with febrile neutropenia presenting to the emergency department. Ann Med 54(1):599\u2013609. https:\/\/doi.org\/10.1080\/07853890.2022.2031271","journal-title":"Ann Med"},{"key":"9562_CR83","doi-asserted-by":"publisher","unstructured":"Coyne CJ, Castillo EM, Shatsky RA, Chan TC (2022) Procalcitonin as a predictive tool for death and ICU admission among febrile neutropenic patients visiting the emergency department. Medicina (Kaunas) 58(8). https:\/\/doi.org\/10.3390\/medicina58080985","DOI":"10.3390\/medicina58080985"},{"issue":"1","key":"9562_CR84","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s10238-021-00734-8","volume":"22","author":"C Intke","year":"2022","unstructured":"Intke C, Korpelainen S, Lappalainen M, V\u00e4nsk\u00e4 M, H\u00e4m\u00e4l\u00e4inen S, Pulkki K et al (2022) Serum caspase-cleaved cytokeratin-18 fragment as a prognostic biomarker in hematological patients with febrile neutropenia. Clin Exp Med 22(1):83\u201393. https:\/\/doi.org\/10.1007\/s10238-021-00734-8","journal-title":"Clin Exp Med"},{"issue":"3","key":"9562_CR85","doi-asserted-by":"publisher","first-page":"e0263623","DOI":"10.1371\/journal.pone.0263623","volume":"17","author":"H Kubo","year":"2022","unstructured":"Kubo H, Imataki O, Kubo YH, Uemura M (2022) c-D-index at day 11 can predict febrile neutropenia during chemotherapy in acute myeloid leukemia. PLoS ONE 17(3). https:\/\/doi.org\/10.1371\/journal.pone.0263623","journal-title":"PLoS ONE"},{"issue":"24","key":"9562_CR86","doi-asserted-by":"publisher","first-page":"3504","DOI":"10.1111\/1759-7714.14720","volume":"13","author":"Y Ono","year":"2022","unstructured":"Ono Y, Hayama N, Hattori S, Ito Y, Oguma T, Sakamaki F et al (2022) Can MASCC and CISNE scores predict delays of lung cancer chemotherapy after febrile neutropenia? Thorac Cancer 13(24):3504\u20133509. https:\/\/doi.org\/10.1111\/1759-7714.14720","journal-title":"Thorac Cancer"},{"key":"9562_CR87","doi-asserted-by":"publisher","unstructured":"Padmanabhan R, Elomri A, Taha RY, El Omri H, Elsabah H, El Omri A (2022) Prediction of multiple clinical complications in cancer patients to ensure hospital preparedness and improved cancer care. Int J Environ Res Public Health 20(1). https:\/\/doi.org\/10.3390\/ijerph20010526","DOI":"10.3390\/ijerph20010526"},{"key":"9562_CR88","doi-asserted-by":"publisher","first-page":"843067","DOI":"10.3389\/fimmu.2022.843067","volume":"13","author":"M Shan","year":"2022","unstructured":"Shan M, Shen D, Song T, Xu W, Qiu H, Chen S et al (2022) The clinical value of procalcitonin in the neutropenic period after allogeneic hematopoietic stem cell transplantation. Front Immunol 13. https:\/\/doi.org\/10.3389\/fimmu.2022.843067","journal-title":"Front Immunol"},{"issue":"3","key":"9562_CR89","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1002\/cam4.4465","volume":"11","author":"MS Ven\u00e4l\u00e4inen","year":"2022","unstructured":"Ven\u00e4l\u00e4inen MS, Heerv\u00e4 E, Hirvonen O, Saraei S, Suomi T, Mikkola T et al (2022) Improved risk prediction of chemotherapy-induced neutropenia-model development and validation with real-world data. Cancer Med 11(3):654\u2013663. https:\/\/doi.org\/10.1002\/cam4.4465","journal-title":"Cancer Med"},{"issue":"1","key":"9562_CR90","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s12672-022-00575-1","volume":"13","author":"R Zatarah","year":"2022","unstructured":"Zatarah R, Faqeer N, Mahmoud A, Quraan T, Matalka L, Kamal A et al (2022) Validation of the (CSR)FENCE score for prediction of febrile neutropenia during chemotherapy cycles 2\u20136. Discov Oncol 13(1):107. https:\/\/doi.org\/10.1007\/s12672-022-00575-1","journal-title":"Discov Oncol"},{"key":"9562_CR91","doi-asserted-by":"publisher","unstructured":"Zatarah R, Faqeer N, Quraan T, Mahmoud A, Matalka L, Abu Khadija L, et al (2022) Validation of the FENCE risk groups for prediction of febrile neutropenia with first-cycle chemotherapy. JNCI cancer spectrum 6(3). https:\/\/doi.org\/10.1093\/jncics\/pkac038","DOI":"10.1093\/jncics\/pkac038"},{"issue":"1\u20132","key":"9562_CR92","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1159\/000519333","volume":"107","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Guo D, Kong X, Liu S, Yu C (2022) A risk-prediction nomogram for neutropenia or febrile neutropenia after etoposide-based chemotherapy in cancer patients: a retrospective cohort study. Pharmacology 107(1\u20132):69\u201380. https:\/\/doi.org\/10.1159\/000519333","journal-title":"Pharmacology"},{"key":"9562_CR93","doi-asserted-by":"publisher","unstructured":"Barros TA, Schaffel R, de Azevedo Neto GS, de Lucena Gaio B, Batista AT, Valentim MR, et al (2023) Application of EBMT, MASCC, and qSOFA scores to predict complicated febrile neutropenia and mortality in autologous stem cell transplant recipients. Hematol Oncol Stem Cell Ther 6(4):370\u20138. https:\/\/doi.org\/10.56875\/2589-0646.1034","DOI":"10.56875\/2589-0646.1034"},{"issue":"3","key":"9562_CR94","doi-asserted-by":"publisher","first-page":"106919","DOI":"10.1016\/j.ijantimicag.2023.106919","volume":"62","author":"H Erdem","year":"2023","unstructured":"Erdem H, Kocoglu E, Ankarali H, El-Sokkary R, Hakamifard A, Karaali R et al (2023) Prospective analysis of febrile neutropenia patients with bacteraemia: the results of an international ID-IRI study. Int J Antimicrob Agents 62(3). https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106919","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"9562_CR95","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1111\/ejh.13952","volume":"110","author":"C Frairia","year":"2023","unstructured":"Frairia C, Nicolino B, Secreto C, Messa E, Arrigo G, Busca A et al (2023) Validation of national early warning score and quick sequential (sepsis-related) organ failure assessment in acute myeloid leukaemia patients treated with intensive chemotherapy. Eur J Haematol 110(6):696\u2013705. https:\/\/doi.org\/10.1111\/ejh.13952","journal-title":"Eur J Haematol"},{"key":"9562_CR96","doi-asserted-by":"publisher","unstructured":"Goto W, Kashiwagi S, Matsuoka K, Iimori N, Kouhashi R, Yabumoto A, et al (2023) Clinical verification on the predictors for febrile neutropenia in breast cancer patients treated with neoadjuvant chemotherapy. Anticancer Res 43(1):247\u201354. https:\/\/doi.org\/10.21873\/anticanres.16156","DOI":"10.21873\/anticanres.16156"},{"issue":"5","key":"9562_CR97","doi-asserted-by":"publisher","first-page":"e0286089","DOI":"10.1371\/journal.pone.0286089","volume":"18","author":"T Rattanathammethee","year":"2023","unstructured":"Rattanathammethee T, Munsamai K, Punnachet T, Hantrakun N, Piriyakhuntorn P, Hantrakool S et al (2023) D-index and invasive fungal infections (IFIs) in adult acute myeloid leukemia (AML) patients with the first episode of febrile neutropenia. PLoS ONE 18(5). https:\/\/doi.org\/10.1371\/journal.pone.0286089","journal-title":"PLoS ONE"},{"key":"9562_CR98","doi-asserted-by":"publisher","first-page":"1122282","DOI":"10.3389\/fmed.2023.1122282","volume":"10","author":"P Thungthong","year":"2023","unstructured":"Thungthong P, Chamnanchanunt S, Suwanban T, Nakhahes C, Iam-Arunthai K, Akrawikrai T et al (2023) The reliability of FEbrile Neutropenia after ChEmotherapy (FENCE) scores in predicting granulocyte colony-stimulating factor breakthrough febrile neutropenia among patients with lymphoma undergoing first-cycle chemotherapy: A prospective observational study. Front Med (Lausanne) 10:1122282. https:\/\/doi.org\/10.3389\/fmed.2023.1122282","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"9562_CR99","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1111\/j.1365-2141.2008.07514.x","volume":"144","author":"R Pettengell","year":"2009","unstructured":"Pettengell R, Bosly A, Szucs TD, Jackisch C, Leonard R, Paridaens R et al (2009) Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU prospective observational european neutropenia study. Br J Haematol 144(5):677\u2013685. https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07514.x","journal-title":"Br J Haematol"},{"issue":"9","key":"9562_CR100","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1002\/cncr.25691","volume":"117","author":"GH Lyman","year":"2011","unstructured":"Lyman GH, Kuderer NM, Crawford J, Wolff DA, Culakova E, Poniewierski MS et al (2011) Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer 117(9):1917\u20131927. https:\/\/doi.org\/10.1002\/cncr.25691","journal-title":"Cancer"},{"issue":"1","key":"9562_CR101","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/annonc\/mdn560","volume":"20","author":"P Jenkins","year":"2009","unstructured":"Jenkins P, Freeman S (2009) Pretreatment haematological laboratory values predict for excessive myelosuppression in patients receiving adjuvant FEC chemotherapy for breast cancer. Ann Oncol\u202f: Off J Euro Soc Med Oncol 20(1):34\u201340. https:\/\/doi.org\/10.1093\/annonc\/mdn560","journal-title":"Ann Oncol : Off J Euro Soc Med Oncol"},{"issue":"16","key":"9562_CR102","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1200\/jco.2000.18.16.3038","volume":"18","author":"J Klastersky","year":"2000","unstructured":"Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R et al (2000) The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol: Off J Am Soc Clin Oncol 18(16):3038\u20133051. https:\/\/doi.org\/10.1200\/jco.2000.18.16.3038","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"10","key":"9562_CR103","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1007\/s00520-015-2650-8","volume":"23","author":"CW Wu","year":"2015","unstructured":"Wu CW, Wu JY, Chen CK, Huang SL, Hsu SC, Lee MT et al (2015) Does procalcitonin, C-reactive protein, or interleukin-6 test have a role in the diagnosis of severe infection in patients with febrile neutropenia? A systematic review and meta-analysis. Support Care Cancer\u202f: Off J Multinatl Assoc Support Care Cancer 23(10):2863\u20132872. https:\/\/doi.org\/10.1007\/s00520-015-2650-8","journal-title":"Support Care Cancer : Off J Multinatl Assoc Support Care Cancer"},{"issue":"4","key":"9562_CR104","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1080\/14787210.2024.2322445","volume":"22","author":"A Gallardo-Pizarro","year":"2024","unstructured":"Gallardo-Pizarro A, Peyrony O, Chumbita M, Monzo-Gallo P, Aiello TF, Teijon-Lumbreras C et al (2024) Improving management of febrile neutropenia in oncology patients: the role of artificial intelligence and machine learning. Expert Rev Anti Infect Ther 22(4):179\u2013187. https:\/\/doi.org\/10.1080\/14787210.2024.2322445","journal-title":"Expert Rev Anti Infect Ther"},{"key":"9562_CR105","doi-asserted-by":"publisher","unstructured":"de Hond AAH, Leeuwenberg AM, Hooft L, Kant IMJ, Nijman SWJ, van Os HJA, et al (2022) Guidelines and quality criteria for artificial intelligence-based prediction models in healthcare: a scoping review. npj Digital Med 5(1):2. https:\/\/doi.org\/10.1038\/s41746-021-00549-7","DOI":"10.1038\/s41746-021-00549-7"},{"key":"9562_CR106","doi-asserted-by":"publisher","unstructured":"Chew CKT, Hogan H, Jani Y (2021) Scoping review exploring the impact of digital systems on processes and outcomes in the care management of acute kidney injury and progress towards establishing learning healthcare systems. BMJ Health Care Inform 28(1). https:\/\/doi.org\/10.1136\/bmjhci-2021-100345","DOI":"10.1136\/bmjhci-2021-100345"},{"key":"9562_CR107","doi-asserted-by":"publisher","first-page":"104596","DOI":"10.1016\/j.ijmedinf.2021.104596","volume":"157","author":"B Sly","year":"2022","unstructured":"Sly B, Russell AW, Sullivan C (2022) Digital interventions to improve safety and quality of inpatient diabetes management: a systematic review. Int J Med Informatics 157. https:\/\/doi.org\/10.1016\/j.ijmedinf.2021.104596","journal-title":"Int J Med Informatics"},{"key":"9562_CR108","doi-asserted-by":"publisher","unstructured":"Bommasani R, Hudson DA, Adeli E, Altman R, Arora S, von Arx S, et al (2021) On the opportunities and risks of foundation models. arXiv preprint arXiv:210807258. https:\/\/doi.org\/10.48550\/arXiv.2108.07258","DOI":"10.48550\/arXiv.2108.07258"},{"issue":"12","key":"9562_CR109","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1093\/jamia\/ocad175","volume":"30","author":"J Lemmon","year":"2023","unstructured":"Lemmon J, Guo LL, Steinberg E, Morse KE, Fleming SL, Aftandilian C et al (2023) Self-supervised machine learning using adult inpatient data produces effective models for pediatric clinical prediction tasks. J Am Med Inform Assoc 30(12):2004\u20132011. https:\/\/doi.org\/10.1093\/jamia\/ocad175","journal-title":"J Am Med Inform Assoc"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09562-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-025-09562-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09562-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T04:02:43Z","timestamp":1753934563000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-025-09562-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":109,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["9562"],"URL":"https:\/\/doi.org\/10.1007\/s00520-025-09562-y","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,4]]},"assertion":[{"value":"29 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a systematic review. No ethics approval was required for the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"537"}}